Key result
His-Purkinje system pacing in patients >85 years was safe and feasible, with clinical event incidences comparable to a younger cohort, except for higher myocardial infarction (8.1% vs 0.7%).
Why the study?
Is His-Purkinje system pacing safe and feasible in patients over 85 years old with symptomatic bradycardia compared to a younger cohort?
Cohort (n=189)
Is His-Purkinje system pacing safe and feasible in patients over 85 years old with symptomatic bradycardia compared to a younger cohort?
His-Purkinje system pacing is feasible and safe in patients over 85 years old with symptomatic bradycardia, demonstrating comparable pacing parameters to younger patients.
Hypothesis-generating for His-Purkinje pacing in patients >85; leaves open MI risk significance pending larger studies.
Introduction: His-Purkinje system (HPS) pacing emerges as an ideal strategy to restore cardiac synchrony. However, there is insufficient evidence to confirm the safety of HPS pacing in advanced age patients who are vulnerable to invasive procedures. Methods: We aimed to evaluate the short-term feasibility and safety of HPS pacing in symptomatic bradycardia patients over 85 years of age by comparing the pacing parameters and clinical outcomes with a younger cohort. 189 out of 198 consecutive patients underwent HPS pacing with symptomatic bradycardia were included. Among them 37 and 152 were aged over 85 years and below 85 years respectively. Peri- and post-procedure pacing parameters, cardiac function and clinical events were thoroughly evaluated during follow-up. Results: Compared with the younger cohort, the elderly had worse renal function and cardiac function. All 189 patients underwent successful HPS pacing, among whom 28 were paced at His-bundle. Paced QRS duration was shortened non-significantly compared with intrinsic, which showed no difference between cohorts. Pacing threshold and impedance decreased significantly without difference between cohorts. Lead dislodgement and pocket hematoma/infection only occurred in 2 (1.3%) and 4 (0.7%) younger patients, respectively. Through a 10.5±3.0 months follow-up, A non-significant improvement in cardiac function was indicated by echocardiographic indices. Clinical events incidences were comparable, except a higher incidence of myocardial infarction (8.1% vs 0.7%) observed in the advanced age cohort. Conclusion: Compared with the younger, HPS pacing could safely restore physiological conduction and reserve cardiac function in advanced age patients with symptomatic bradycardia.
No takes yet. Share an insight, caveat, or question.
Ren et al. (2020) conducted a cohort in Symptomatic bradycardia (n=189). His-Purkinje system (HPS) pacing in patients >85 years vs. His-Purkinje system (HPS) pacing in patients <85 years was evaluated on Pacing parameters, cardiac function and clinical events. His-Purkinje system pacing in patients >85 years was safe and feasible, with clinical event incidences comparable to a younger cohort, except for higher myocardial infarction (8.1% vs 0.7%).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: